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"Here in Singapore the abuse of heroin has
increased alarmingly - a small epidemic to
quote the Govt. Schoolchildren in their early
teens are now involved. The govt. has brought
in very tough legislation, A person found in
possession of more than 3 g (Gm) morphine or
2 g heroin is presumed, until contrary is
proved, to be a drug trafficker. Maximum
sentence is 20 years and 20 strokes of the
cane. For trafficking in more than 15 g of
heroin (or 30 g morphine) the penalty is
death, One such case will be coming up to the
courts soon. Suspected abusers must supply
urine samples for tests and if any controlled
drug is found in the urine, the person is presumed to have consumed the drug and thus
committed an offence. Thus it will not be a
defence, as before, that the person may have
been administered the drug without his knowledge in a drink, cigarette etc. He is guilty
unless he can prove his innocence."
Personal Communication ( A1:1 to JKB) April 197 6.
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THE USE OF NARCOTIC ANTAGONISTS IN RELATION TO OPIATE-TYPE DRUG DEPENDENCE
Fries, PhD and William G. Reifenrath, PhD; Section of Medicinal Chemistry, School of
, University of the Pacific, Stockton, California 95211
·
INTRODUCTION
Narcotic antagonists are drugs which reverse the pharmacological effects of morphine,

other narcotic analgetics. The first narcotic antagonist was reported by Pohl(l).
to improve the analgetic (pain-killing) properties of codeine, he synthesized
noJrccJaE•~n.e and found that it unexpectedly antagonized the respiratory depression and

by morphine. This finding lay dormant until the synthesis of N-allylnormorphine
which was found to antagonize most of the actions of morphine(4). The initial

~Jor]pn:cn,,,(2,3)

of nalorphine lYas to test for physical dependence in individuals suspected to be
to heroin-like agents. Later nalorphine was realized to be life saving in cases of
overdose. Continued studies also revealed nalorphine to have strong analgetic prop-

man.

These -interesting properties of nalorphine provided the impetus for development

narcotic antagonists and also of other compounds possessing a mixture of analgetic and

properties.
Recently narcotic antagonists have been studied for use in postdetoxification treatment of

, with the aim that pretreatment of individuals with an antagonist will provide protect the pharmacological actions of those narcotics responsible for heroin-like drug

(5).
review is an attempt to explain the current status of narcotic antagonists as they

drug therapy (treatment of opiate overdosage) and drug abuse (management of the post
opiate addict). All individuals using these agents should have a thorough underof their pharmacological actions. These narcotic antagonists are currently the most
antidote available for heroin overdosage and act within seconds o f injection. They are
saving compounds and are stocked in the emergency rooms of practically all hospitals today.

CHEMISTRY
Narcotic antagonists are structurally very similar to parent narcotic agents.

At this time

clinically useful antagonists have resulted from the replacement of the N-methyl group on
parent narcotic with an N-allyl or N-methylcyclopropyl group. The structures and names of
narcotic antagonists that are curre;tly available are given in Table I.

general, antagonists with an N-methylcyclopropyl (as in cyclazocine) group have a longer
of action than those with an-N-allyl moiety (nalorphine, naloxone, and levallorphan).

~·'"''u'·"un of hydroxyl at the 14-position of the morphine nucleus (as in naloxone) imparts
and purer antagonistic activity. The 4-5 ether bridge in nalorphine or naloxone does
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for antagonist activity a nd may promote fast er metabolism a t the C-3 posia desirable feature in the design of longer acting antagonists(6).

4.

Table I.

Currently Marketed Narcotic Antagonists

PHARMACOLOGY
Narcotic antagonists are capable of reversing effects such as analgesia, sedation, eupho-

NARCOTIC ANTAGONIST

PARENT NARCOTIC

STRUCTURE

~

R

Name

R

Name

gastrointestinal effects, and the frequently lethal respiratory depression caused by morand its surrogates. These antagonists are specific in that they will not reverse depres ting from oth er classes of drugs such as barbiturates. They are also worthless in
overdosage with stimulants (such as cocaine and the amphetamines).

However

naloxone

recently been reported to reverse the effects of large doses of diazepam (Va liumR)(7).

-)

ROO

0

- CH

Morphine

3

Nalorphi~e

(Nalline )

-CH

.

0

Nalorphine and levallorphan are termed partial-antagonis ts or mixed agonist- antagonists for
following reasons. lfhen these agents are administered to normal persons, they mimic to
degrees the effects seen with morphine administration (agonist effects). However, when
a re given to persons dependent on opiates or who have opiates present in their
, these partial antagonists 11 reverse 11 the effec t s of the opiate. Naloxone displays very
if any agonist effects when given to norma ls and is therefore terme d a pure antagonist.
pentazocine is a mixed agonist-antagonist, its antagonist compone nt is weak and it is
useful in cases of narcotic overdose. It is used primarily as an analgetic .

:

~(-)
HO

-cH -CH=CH
2
2

3

Oxomorphone

-cH -CH=CH
2
2

Naloxollft
(Narcan )

general the agonist- antagonists have a low potential for drug dependence. In studies
chronic administration of nalorphine, cyclazocine and pentazocine, abrupt withdrawal
an abstinence syndrome which was relatively mild compared to morphine (8,9,10). Assowith their agonist component, these agents can produc e significant respiratory depres-

Agents of this class can also pr oduce psychotomimetic effects (disorientation, halluci' etc.), particularly when both agonist and antagonist properties are strong(ll) .

0

©G-1

pure antagonists (naloxone) by definition have no agonist properties . They will not
analgesia, respiratory depression, pupillary constriction, or psychotomimetic effects
ical dependence is not possible. Tolerance to the antagonist properties is also not
on chronic administration(ll,l2).
-CH

3

Levorphanol

- cH -CH=CH
2
2

LevalloRphan
(Lorfan )
~r•a t E•-induced

HO

be emphasized again that these antagonists will not reverse respiratory depresthe barbiturates. In fact, nalorphine and levallorphan may even worsen barbior al cohol-induced respiratory depression because of their ago nist activity. In
the cause of respiratory depression is not clear, or if drugs in addition to

suspected in the depression, naloxone is indicated since it produces no respiratory

its own.

~·

'• , CH

0

(±)

3

It should also be cautioned that administration of a ny antagonist to

precipitate a severe withdrawal syndrome which can be more dangerous than the res depression; however, administration of the antagonists in small doses over a period of
minutes will reduce the chance of this happening. Further, narcotic overdose cases

-cH

3

Metazocine

-CH -CH=C(CH )2
3
2

PentazoRine
(Talwin )

1 ,,~•c c.La''~Y methadone) treated with antagonists should be observed period ical ly , since the dura-

the antagonist may be shorter than the narcotic causing the respiratory depression. The
of the antagonist may wear off before those of the narcotic, and life-threatening resdepression may again result, requiring the administration of more antagonist.

Over-

patients should always be under qualified medical supervision.

3

Nalorphine (Nalline HClR, Merck, Sharp and Dohme) .

Nalorphine shows little evidence of

activity in most animal studies except in the rat.

as morphine(l3).

However, in man it is as potent

As is typical of partial antagonists, "addiction" liability is

to morphine or heroin.
analgetic doses .

Unfortunately, the compound produces psychotomimetic

absorbed after subcutaneous administration and quickly crosses the
site of action. It is excreted rapidly via the urine. Its duration
shorter than its parent compound, morphine .

Numbering of Morphine Ring System
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is useful in the treatment of narcotic overdosage to combat the severe respiracaused by morphine, codeine, heroin, and similar agents . Nalorphine has also
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6.
been used as a diagnostic agent for opiate abuse (Nalline test)--a positive response being
cated by a prompt increase in pupil size(l4). Tests of this kind should only be done by
cians well acquainted with the procedure. The reliability of the test has been questioned
the use of sensitive chemical tests for the presence of opiates in the urine are preferable
medically and in courts of law(l5).

7.
of physical dependence is not possible in these circumstances. Further, if compulopiate use is a result of reinforcement of drug seeking behavior due to euphoric effects of
drugs, the use of antagonists should extinguish this behavior(22,23).

addicts.

Levallorphan (Lorphan TartrateR, Roche). Levallorphan has twice the potency of
as an antagonist and has comparable analgetic potency(l6,17). As with nalorphine, its
of action is significantly shorter than its parent, levorphanol. Its overall actions and
are similar to those of nalorphine, and similar precautions should be taken in its
Naloxone (NarcanR, Endo). Naloxone is approximately 7 times more potent than nalorphine
an antagonist. It produces negligible side effects in normal subjects at therapeutic
Naloxone will inhibit or reverse the effects of all opiate agonists such as morphine,
methadone, propoxyphene (DarvonR) and meperidine (DemerolR) , Unlike nalorphine and
naloxone is an effective antagonist of the respiratory depression caused by
other antagonists(ll). Because naloxone is a potent, fast-acting (effects noticed
2 minutes following intravenous administration and slightly longer intramuscularly), pure narcotic antagonist that produces no respiratory depression, it is the drug of choice to combat
respiratory depression resulting from opiate overdose. Since naloxone does not alter respiratory depression caused by barbiturates or other sedative-hypnotics, failure to get a response
from naloxone is a good indication that the depression is not caused by an opiate.

compounds presently being investig a ted as agents for treatment
These include cyclazocine, oxilorphan and naltrexone (see struc-

NY

~·.,.
'Me

Naloxone treatment has been proposed as a means to prevent addicts from returning to drug
use, but its short duration of action (effective levels of naloxone can be maintained in man
for only 4 hours) (17) and poor oral activity (1-3 grams/day are required to protect against the
effects of heroin for 24 hours)(l9) limit its use for this purpose.

The low oral activity of naloxone (50 times less potent orally than parenterally) is utilized in a preparation called MethenexR (Bristol) . This product is formulated to provide a
ratio of 40 mg methadone HCl to 2 mg naloxone HCl. When given orally at the usual doses, the
naloxone present does not interfere with the effects of methadone .

However, administration of

this mixture by injection results in significant reduction of the pleasing effects caused by
methadone, thereby reducing the attractiveness of the mixture for abuse by injection(20) .

@f6
HO

0

Cyclazocine

Oxilorphan

NJ>

~
.

Naltrexone

Cyclazocine. Cyclazocine has both potent agonist and antagonist activities . Cyclazocine
ection is approximately 40 times more potent than morphine as an analgetic(24). Its
t potency is slightly less than naloxone(l6) . Like nalorphine and levallorphan, cyclacapable of producing marked respiratory depression. Although chronic administration
to human subjects produces an abstinence syndrome on abrupt withdrawal, the

is mild compared to morphine.

Pentazocine (TalwinR, Winthrop) . The only antagonist currently marketed as an analgetic
In doses of approximately 4 mg/day orally, cyclazocine has been found to antagonize the
pentazocine . The presence of both agonist and antagonist activity in pentazocine has been
of morphine administration for 24 hours--a mode of administration and duration of action
demonstrated. As an analgetic it is 1/3 as potent as morphine on injection and roughly equifor use in post-withdrawal treatment programs(5,9,18). However, the compound produces
potent to codeine orally(21). Pentazocine has relatively weak antagonist activity, being 1/50
• hallucinations, irritability and sedation. Although thes e side effects increase in
as potent as nalorphine in precipitating abstinence in subjects dependent on 240 mg/day of marthe dose increases(25,26), they usually, but not always, dis a pp ear on continued
phine(8). It is not used for treatment of narcotic overdoses . In general, pentazocine at the otntot·r•''On. Tolerance does not develop to the antagonist activity(25). Cy clazocine's unu sual doses produces typical opiate CNS effects including analgesia, sedation and respiratory
side effects, particularly during induction, would appear to pr event its widespread
depression, but at higher doses produces nalorphine-like dysphoria (restlessness and anxi~ty)
use(l9,27).
It is ~ell absorbed from the gastrointestinal tract and from subcutaneous and intramuscular
Oxilorphan has weak agonist and predominant ant agonist pr ope rties. It has a n
sites . As is typical of mixed agonist-antagonists, pentazocine's dependence liability is low
potency similar to cyclazo c ine and it appears to have a long dura tion of action(28).
and withdrawal from chronically administered pentazocine has been judged 1/3 as severe as morbeen proposed for use in narcotic post-withdrawal treatment programs a nd studies are curphine . If pentazocine is administered to subjects dependent on opiates, the possibility of
underway to determine the efficacy of oral administration, duration of antagonist activcipitating a withdrawal syndrome is present--the intensity of which is related to the level
and
the level of side effe cts.
dependence and the dose of pentazocine given . In patients receiving opiates on a regular
an opiate-free period of 1-2 days before pentazocine administration will usually suffice
vent withdrawal effects . Pentazocine has the ability to depress respiration, and in cases
Naltrexone. Naltrexone is a pure antagonist wi th greater potency than naloxone . Having
overdose the respiratory depression cannot be countered by nalorphine or levallorphan . ~. l nw>ne l~t>nl. st properties, euphoria or physical dependence is not possible. In doses of 50-200 mg
has been reported effective in this. regard.
in clinical studies, negligible effects were observed(l2,29). It is orally active and
te doses gives a duration of protection against opiate effects comparable to that
with cyclazocine(30). Little toxicity data is available for naltrexone, and studies
underway to determine its safety and utility for post-withdraw! treatment .
ANTAGONISTS IN NARCOTIC ADDICTION TREATMENT
Narcotic antagonists were proposed some time ago for use by post-withdrawal addicts.
Ideally, if these individuals are continuously taking sufficient amounts of a narcotic antagonist, the effects of ordinary doses of opiates are significantly reduced or blocked entirely.
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In summary, the results from studies investigating the effica cy of using an antagonist drug
rehabilitation of addicts have not been impressive when compared to the methadone-mainapproach--particularly with regard to the percentage of pati ents becoming socially
and the attractiveness of the method to the addict population(l8,27,31,38). Treat-
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ment with antagonists appears to require a well motivated subject with a relatively moderat

habit(27).

The dysphoric effects of cyclazocine and oxilorphan probably will prevent thesee

from ever attaining widespread clinical use. Agents such ·as naloxone or naltrexone provide
euphoria or reinforcing properties for the former addict and, since this individual

get relief from heroin when life seems intolerable, he may turn to other depressant
alcohol or barbiturates.
The authors can see two possible modes by which narcotic antagonists may someday become
ful in drug rehabilitation therapy. The first of these would require that courts of law
participation in the programs mandatory for parolees whose criminal records are directly
to use of the opiate drugs. The second would require the development of a new antagoni
would both block the action of heroin, and induce pharmacological effects which are
enough to substitute for the drug response which the individual is seeking. Whether such a

current research to develop antagonists of long duration through modification of the dosage
of existing ant.agonists is in progress. Most clinicians indicate a preference for an
of s.everal days or weeks duration, as this would require less motivation of former

in rehabilitation programs. In one study, to determine the feasibility of slow-release
of naltrexone, the drug was suspended in small particles of polylactide plastic. In
dose blocked the effects of .morphine for a period of 20-30 days(38). Alza CorAlto, California, is also examining the development of polymers that can.be used
of drugs, including naloxone, to provide slow release.

At the present t1me, all

preparations require much further testing and clinical study to determine their safety
utility·
SUMMARY

can be found remains to be seen.
antagonists to counter life-threatening respiratory depression result-

is well established. The role of antagonists in post-withdrawal manof the addict is yet to be determined. Certainly the antagonists should not be regarded
answer to opiate abuse, but rather as a potentially powerful tool to aid the clini:ian

CURRENT RESEARCH
All of the compounds discussed above have chemical structures closely related to morphine.
In the continuing search for analgetics superior to morphine, simpler compounds with mixed

agonist-antagonist properties are being investigated. The bridged aminotetralins(33), the
levo-isomer of 5-~-hydroxyphenyl-2-methylmorphan(34), profedol(35), prodilidine(35), and viminol(36) are among these interesting compounds. However, none of these compounds have yet
clinical usefulness.

c.? cf2,
~~,~~'"'"'' .~
0

OH

Researchers cont1nue

investigate the antagonists not only with the hope of discovering more effective
for the treatment of heroin-like drug dependence, but also of finding a strong analgetic,
of side effects and without potential for dependence.
REFERENCES

OH

-Me

,,,,

n
Bridged Aminotetralins

worker in the overall treatment of narcotic drug dependence.

2-methylmorphan

Profedol

N

I
Me
Prodilidine

Viminol
Compounds of even·more complex structure than morphine have been synthesized.

a bridged derivative of thebaine, has been proposed for clinical trials because of
pharmacological results in animals(37). The compound has shown potent agonist and antagonis t
activity in rodents. It does not produce physical dependence on chronic administration to mice
or monkeys. In clinical studies at doses of 2 ~g/kg intravenously or intramuscularly and
40 ~g/kg orally, doses which have shown significant blockade of experimentally-induced pain, no
signs of dysphoria were observed.

Pohl, J.Z., J. Exp. Path. Ther., 17, 370 (1915).
McCawley, W.L., Hart, E.R. and Marsch, D.F., J. Am. Chern. Soc., 63, 314 (1941).
Weijlard, J. and Erickson, A.E., ibid., 64, 869 (1942) .
Unna, J,, J, Pharmacal. Exp. Ther., J..2., 27 (1943).
Martin, W.R., Gorodetzky, C.W. and McClane, T.K., Clin. Pharmacal. Ther., 7, 455 (1966).
Pachter, I.J. In: Narcotic Antagonists, (edit. H.C. Braude, L.S. Harris, E.L. May,
J.P. Smith and J.E. Villarreal). Advances in Biochemical Psychopharmacology, Volume 8,
Raven Press, New York, (1974), pp. 57-62.
Bell, E.F., J. Pediat., ~' 803 (1975).
Jasinski, D.R., Martin, W.R. and Hoeldtke, R.D., Clin. Pharmacal. Ther., 11, 385 (1970).
Martin, W.R., Fraser, H.F., Gorodetzky, C.W . and Rosenberg, D.E., J. Pharmacal . Exp. Ther.,
150, 426 (1965),
Martin, W.R. and Gorodetzky, C.W., .!.!?.!.'!·, 150, 437 (1965).
Jasinski, D.R., Martin, W.R. and Sapira, J.D., Clin. Pharmacal. Ther., 9, 215 (1968).
Martin, W.R., Jasinski, D.R. and Mansky, P.A., Arch . Gen. Psychiatry, 28, 784 (1973).
Lasagna, L. and Beecher, H.K., J. Pharmacal. Exp. Ther., 112, 356 (1954).
Elliott, H.W. In: Narcotic Drugs-Biochemical Pharmacology, (edit. D.H. Clouet), Plenum
Press, New York, (1971), pp. 484-492.
Kaistha, K.K. and Jaffe, J.H., J. Pharm. Sci., 61, 305 (1972).
Gorodetzky, C.W. In: Narcotic Antagonists, (edit. M.C. Braude, L.S. Harris, E.L. May,
J. P. Smith and J.E. Villarreal). Advances in Biochemical Psychopharmacology, Volume 8,
Raven Press, New York, (1974), pp. 291-297.
Martin, W.R., Pharmacal. Rev., l2_, 463-521 (1967).
Fink, M., Zaks, A., Sharoff, R., Hora, A., Bruner, A., Levit, S. and Freedman, A.M., Clin.

Pharmacal. Ther., 9, 568 (1968).
Zaks, A., Jones, T~, Fink, M. and Freedman, A.M., J. Am. Med. Assn., 215, 2108 (1971).
Nutt, J.G. and Jasinski, D.R., Clin. Pharmacal. Ther., 15, 156 (1974).
Brogden, R.M., Speight, T. M. and Avery, G.S., Drugs, 2• 6-91, (1973).
Wikler, A. In: Narcotics, (edit. D.M. Wilner and G.G. Kassebaum), McGraw-Hill, New York,
(1965), pp. 85-100.
Wikler, A. and Pescor, F.T., Psychopharmacologia, 10, 255 (1967).
Lasagna, L., DeKornfeld, T.J. and Pearson, J.W., J. Pharmacal. Exp . Ther., 144, 12 (1964)
Jaffe, J.H. and Brill, 1., Int. J. Addict., l, 99 (1966).

Buprenorphine

Pacific Information Service on Street -Drugs

Volume 5
May,

Information Service on Street-Drugs

Volume 5 No. 1
May,

1976

10.
(26)
(27)

Resnick, R., Fink, M. and. Freedman, A.M., Amer. J. Psychiatry, 131, 595 (1974).
Klebner, H., Kinsella, J., Riordan, C., Greaves, S. and Sweeney, D., ~~~~~~~~l,ttl
30, 37 (1974).
(28) 1'Trdo, A.W. and Gylys, J.A., J. Pharmacol. Exp. Ther., 193, 23 (1975).
(29) Schecter, A., Friedman, J. and Grossman, D., Am. J. Drug~c. Abuse, !• 253 (1974).
(30) Resnick, R., Volavka, J., Freedman, A.M., Jones, T. and Thomas, M.J., Am. J. Psych~,
131, 646 (1974).
(31) Freedman, A.M., Fink, M., Sharoff, R. and Zaks, A., J. Am. Med. Assoc., 202, 191 (1967).
(32) Jaffe, J.H. In: Current Psychiatric Therapies, (edit. J. Masserman), Grune & Stratton
Inc., New York, (1967) pp. 147-156.
(33) Freed, M.E., Potoski, J.R., Freed, E.M., Gluckman, M.I. and Mallis, J.C. In: Narcotic
Antagonists, (edit. M.G. Braude, L.S. Harris, E.L. May, J.P. Smith and J.E. Villarr;ar)
Advances in Biochemical Psychopharmacology, Volume 8, Raven Press, New York, (1974),
PP• 137-144.
(34) Ong, M.H., Oh-ishi, T. and May, E.L., J. Med. Chern., 17, 133 (1974).
(35) McCarthy, D.A. In: Narcotic Antagonists, (edit. M.C~Braude, L.S. Harris, E.L. May,
J.P. Smith and J.E. Villarreal) Advances in Biochemical Psychopharmacology, Volume 8,
Raven Press, New York, (1974), pp. 145-155.
(36) Della Bella, D., Ferrari, V., Friegeni, V. and Lauldi, P., Nature-New Biology, 241,
282 (1973).
(37) Lewis, J.W. In: Narcotic Antagonists, (edit. M.G. Braude, L.s·. Harris, E.L. May, J.P.
Smith and J.E. Villarreal), Advances in Biochemical Psychopharmacology, Volume 8, Raven
Press, New York (1974), pp. 123.
(38) Martin, W.R. and Sandquist, V.L., Arch. Gen . Psychiatry, 30, 31, (1974).

NEWS AND COMMENT
A new street-drug analysis laboratory. Further information may be obtained
writing to:
The Branan Drug Analysis and Toxicology Laboratory,
345 Boulevard, N. E.
Altlanta, Georgia 30312
Telephone (404) 688-4400
An excellent publication has just come to our attention and we are listing i
because it does seem to fulfill a need in toxicology.
Charles L. Winek, Editor and Sydney P. Shanor, Assistant Editor
TOXICOLOGY ANNUAL 1974
New York NY: Marcel Dekker, Inc., 1975
A very interesting article related to the topic in this issue
is ln the above publication.

Another publication has come to our attention (1~e have not seen a copy) that
could be very useful in street-drug analysis.
N. H. Choulis.
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